Van Eck Associates Corp Biogen Inc. Transaction History

Van Eck Associates Corp

$64.4 Billion
Q1 2024

A detailed history of Van Eck Associates Corp transactions in Biogen Inc. stock. As of the latest transaction made, Van Eck Associates Corp holds 1,737,340 shares of BIIB stock, worth $403 Million. This represents 0.58% of its overall portfolio holdings.

Number of Shares

1,737,340

Previous 1,421,196 22.24%

Holding current value

$403 Million

Previous $368 Million 1.87%

% of portfolio

0.58%

Previous 0.67%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 30, 2024	BUY	$212.02 - $267.71 $67 Million - $84.6 Million	316,144 Added 22.24%	1,737,340 $375 Million
Q4 2023 Feb 05, 2024	BUY	$222.59 - $267.94 $51.6 Million - $62.1 Million	231,650 Added 19.47%	1,421,196 $368 Million
Q3 2023 Nov 08, 2023	BUY	$253.3 - $285.89 $59.2 Million - $66.9 Million	233,889 Added 24.47%	1,189,546 $306 Million
Q2 2023 Aug 03, 2023	BUY	$275.25 - $318.06 $40 Million - $46.2 Million	145,279 Added 17.93%	955,657 $272 Million
Q1 2023 May 03, 2023	BUY	$256.56 - $292.34 $5.85 Million - $6.67 Million	22,820 Added 2.9%	810,378 $225 Million

Q4 2022 Feb 08, 2023	SELL	$252.44 - $306.72 $32.9 Million - $40 Million	-130,428 Reduced 14.21%	787,558 $218 Million
Q3 2022 Oct 27, 2022	SELL	$194.69 - $268.46 $6.2 Million - $8.55 Million	-31,849 Reduced 3.35%	917,986 $245 Million
Q2 2022 Aug 03, 2022	BUY	$187.54 - $223.02 $2.24 Million - $2.67 Million	11,957 Added 1.27%	949,835 $194 Million
Q1 2022 May 10, 2022	BUY	$193.77 - $244.14 $26.9 Million - $33.9 Million	138,949 Added 17.39%	937,878 $198 Million
Q4 2021 Jan 26, 2022	BUY	$223.92 - $287.77 $35.6 Million - $45.7 Million	158,854 Added 24.82%	798,929 $192 Million
Q3 2021 Nov 03, 2021	BUY	$282.99 - $369.05 $12.3 Million - $16.1 Million	43,528 Added 7.3%	640,075 $181 Million
Q2 2021 Aug 10, 2021	SELL	$259.0 - $414.71 $7.12 Million - $11.4 Million	-27,497 Reduced 4.41%	596,547 $207 Million
Q1 2021 May 13, 2021	BUY	$242.95 - $284.63 $26 Million - $30.5 Million	107,220 Added 20.75%	624,044 $175 Million
Q4 2020 Feb 09, 2021	BUY	$236.26 - $355.63 $19.2 Million - $29 Million	81,406 Added 18.7%	516,824 $127 Million
Q3 2020 Nov 12, 2020	BUY	$264.77 - $305.71 $13 Million - $15 Million	49,103 Added 12.71%	435,418 $124 Million
Q2 2020 Aug 10, 2020	BUY	$258.66 - $342.55 $9.68 Million - $12.8 Million	37,434 Added 10.73%	386,315 $103 Million
Q1 2020 May 12, 2020	SELL	$268.85 - $341.04 $16.1 Million - $20.5 Million	-60,015 Reduced 14.68%	348,881 $110 Million
Q4 2019 Feb 13, 2020	BUY	$220.06 - $304.07 $10.3 Million - $14.3 Million	46,897 Added 12.96%	408,896 $121 Million
Q3 2019 Nov 08, 2019	BUY	$217.44 - $243.88 $11.3 Million - $12.7 Million	51,931 Added 16.75%	361,999 $84.3 Million
Q2 2019 Aug 07, 2019	BUY	$219.29 - $241.72 $13.2 Million - $14.6 Million	60,339 Added 24.16%	310,068 $72.5 Million
Q1 2019 May 13, 2019	BUY	$216.71 - $338.96 $7.38 Million - $11.5 Million	34,036 Added 15.78%	249,729 $59 Million
Q4 2018 Feb 12, 2019	BUY	$278.5 - $352.75 $2.69 Million - $3.4 Million	9,644 Added 4.68%	215,693 $64.9 Million
Q3 2018 Nov 13, 2018	SELL	$293.51 - $383.83 $2.31 Million - $3.02 Million	-7,859 Reduced 3.67%	206,049 $72.8 Million
Q2 2018 Aug 13, 2018	BUY	$257.52 - $306.91 $2.53 Million - $3.01 Million	9,806 Added 4.8%	213,908 $62.1 Million
Q1 2018 May 11, 2018	SELL	$260.13 - $367.91 $6.19 Million - $8.76 Million	-23,802 Reduced 10.44%	204,102 $55.9 Million
Q4 2017 Feb 12, 2018	SELL	$307.64 - $344.58 $2.33 Million - $2.61 Million	-7,578 Reduced 3.22%	227,904 $72.6 Million
Q3 2017 Nov 09, 2017	SELL	$281.15 - $329.69 $5.99 Million - $7.02 Million	-21,295 Reduced 8.29%	235,482 $73.7 Million
Q2 2017 Aug 11, 2017	BUY	N/A	256,777	256,777 $69.7 Million

Others Institutions Holding BIIB

# of Institutions

1,046

Shares Held

126M

Call Options Held

1.37M

Put Options Held

1.35M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $33.4B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

News

Stay updated on Van Eck Associates Corp with notifications on news.

Account

Van Eck Associates Corp Biogen Inc. Transaction History